Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page & e5 L. p9 ^" \
6 C9 y q, [6 ^" v# a- J& }
6 A5 |$ R) `* ~9 C- q! ~8 FSub-category:$ a9 ]$ S1 n/ w t2 l; ^; i
Molecular Targets % H/ y2 N( B4 U/ R# Z6 v8 r
% ^; E& I& W& s4 e: p
2 |1 R; f0 s; ?. X
Category:& F+ z+ K3 ~! l" V
Tumor Biology - q8 m' U6 C, S( {$ A
5 f) m2 l( Y* S4 C* }' T# x: ^
' J$ `) V6 \/ U$ }8 c }Meeting:: G. Q+ s/ F4 }) e3 j
2011 ASCO Annual Meeting
% K5 [0 C5 {! Y2 I7 t2 Q$ P: u* T+ q) h! O' ^9 O- Y
+ I4 C3 i3 _2 b$ C& E6 y4 T
Session Type and Session Title:
0 g; c. P" Q( {Poster Discussion Session, Tumor Biology + A* Y$ P4 I5 x
; m( J6 s; h' x0 ~0 Z0 o( B" E9 j4 D3 p# R z
Abstract No:
g* E" O. W- u& B, q; ?10517
6 `1 f. W9 a- _1 x- Q% E
9 i$ {" H: U" t# u4 \6 } P0 A% w% G* @9 P- c- ?
Citation:
+ Y9 r% @. ]4 tJ Clin Oncol 29: 2011 (suppl; abstr 10517)
* \5 z! i( H Q1 L1 ^/ U+ D% r; S0 B
9 p7 [& {% S7 S1 s k& X* @2 o
Author(s):
) l8 R N) `$ H" ^J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China , p& V) q7 M& x; r' a2 ^/ a
$ e2 O# o4 |) t2 V9 ?
, R' W7 z9 ~) |) u' B$ p
4 _. m$ W! J" ~( M5 }1 \. V* k
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
; d( d/ j4 P* o: I. f3 Y0 z% h- k" d* O, d9 x) O
Abstract Disclosures* `$ p. [( }/ p; K+ k) c- Z+ i
+ [( _' I# V, x `) @/ ]3 PAbstract:4 |9 G% c. `; l. d* {6 R5 T
! {% h$ a$ m2 b3 W* S9 }$ o
N% v+ J6 S4 eBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 m4 _2 E* ?& W* G9 f" r! e
' V- B; y# m# v" `+ u
: [; w/ D/ u7 n/ P+ s% p |
母亲奥希替尼耐药 求耐药后续方案
母亲肺腺癌晚期服用奥希替尼两年耐药，做了胸膜穿刺取组织基因检测，求后续的治疗方案
病理报告为（直乙交界处）粘液腺癌，
1、3-4月腹痛不止，且如厕困难5月肠镜病理报告为癌（期间做过B超、ct、增强ct、血常规
奥西耐药换伏美三个月耐药，求后续治
母亲，刚满69岁，2021年1月底确诊肺腺癌四期，双肺、双侧胸膜转移，L858R 21突变，目
母亲晚期肺癌跨越13年，这是我家长期
讲述者：不怕辣椒不怕癌整理者：雪漓
在我家抗癌跨越10年之际，鹰版就曾邀请我写一篇
新策略！肺癌EGFR基因L858R突变只用
本帖源自与最近癌度的一篇公众号文章，这可能也是我这些年写的自我感觉比较重要的文章
显身卡
